Evidence map›Paper›PMID 37844795›Full record

ArticleCellular and molecular gastroenterology and hepatology2024

GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.

Kathleen R Smith, Wenshan Wang, Melissa R Miller, Magalie Boucher, Jessica E Reynold, Natalie A Daurio, Dongmei Li, Dinesh Hirenallur-Shanthappa, Youngwook Ahn, David A Beebe and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Recombinant Macrophage Migration Inhibitory Factor Derived fromInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Fatty Acid Esterification as a NASH Therapeutic Target.Cellular and molecular gastroenterology and hepatology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kathleen R SmithWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Wenshan WangWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Melissa R MillerWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Magalie BoucherWRDM Drug Safety, Research and Development, Pfizer Inc, Groton, Connecticut.
Jessica E ReynoldWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Natalie A DaurioWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Dongmei LiWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Dinesh Hirenallur-ShanthappaWRDM Comparative Medicine, Pfizer Inc, Cambridge, Massachusetts.
Youngwook AhnWRDM Target Sciences, Pfizer Inc, Cambridge, Massachusetts.
David A BeebeWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Kenneth L KellyWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Trenton T RossWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Kendra K BenceWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.
Min WanWRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts. Electronic address: Min.Wan@pfizer.com.
Pfizer (United States) · USTarget (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsNonalcoholic fatty liver disease (NAFLD), and its more severe form, nonalcoholic steatohepatitis (NASH), is the leading cause for liver failure and liver cancer. Although the etiology is likely multifactorial, genes involved in regulating lipid metabolism are enriched in human NAFLD genome-wide association studies (GWAS), pointing to dysregulated lipid metabolism as a major pathogenic factor. Glycerol-3-phosphate acyltransferase 1 (GPAT1), encoded by GPAM, converts acyl-CoAs and glycerol-3-phosphate into lysophosphatidic acid and has been shown to regulate lipid accumulation in the liver. However, its role in mediating the progression from NAFLD to NASH has not been explored.

methodsGPAT1-deficient mice were generated and challenged with diets inducing hepatic steatosis and NASH. Effects of GPAT1 deficiency on lipid and systemic metabolic end points were evaluated.

resultsAblating GPAT1 globally or specifically in mouse hepatocytes reduced hepatic steatosis in the context of diet-induced or genetic obesity. Interestingly, blunting of progression from NAFLD to NASH in global GPAT1 knockout (KO) mice was model dependent. GPAT1 KO mice were protected from choline deficient, amino acid defined high-fat diet-induced NASH development, but not from the high fat, high carbohydrate, and high cholesterol diet-induced NASH.

conclusionsOur preclinical data support the notion that lipid metabolism pathways regulated by GPAT1 in hepatocytes play an essential role in NASH progression, albeit in a model-dependent manner.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsDiet, High-FatGenome-Wide Association StudyGlycerolHumansLipidsMiceMice, KnockoutPhosphatesGlycerolLipidsPhosphatesGPAT1Hepatic SteatosisLiver Inflammation and FibrosisNASHNASH Mouse Models

Identifiers

PMID37844795
PMCPMC10829521
OpenAlexW4387639161

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.